Innovative Eyewear Inc. (LUCY)vsNovartis AG ADR (NVS)
LUCY
Innovative Eyewear Inc.
$1.05
+0.96%
HEALTHCARE · Cap: $6.49M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2125534% more annual revenue ($56.58B vs $2.66M). NVS leads profitability with a 23.9% profit margin vs -285.2%. NVS earns a higher WallStSmart Score of 51/100 (C-).
LUCY
Hold36
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+39.2%
Fair Value
$1.81
Current Price
$1.05
$0.76 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 39.0% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -83.6% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : LUCY
The strongest argument for LUCY centers on Price/Book, Revenue Growth. Revenue growth of 39.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : LUCY
The primary concerns for LUCY are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
LUCY profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
LUCY carries more volatility with a beta of 3.06 — expect wider price swings.
LUCY is growing revenue faster at 39.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 36/100), backed by strong 23.9% margins. LUCY offers better value entry with a 39.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Innovative Eyewear Inc.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Innovative Eyewear Inc. (LUCY) is a pioneering player in the smart eyewear sector, skillfully merging advanced technology with modern aesthetics to meet the needs of tech-savvy consumers. Its flagship line, Lucyd, stands out by integrating audio features and connectivity into stylish eyewear, thus providing both versatility and fashion. With a strong focus on innovation and enhancing user experiences, the company is well-positioned to harness the growing demand for multifunctional wearables, indicating significant growth potential in the rapidly evolving eyewear market. As trends shift towards smart solutions, LUCY's strategic approach positions it favorably for long-term success.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?